MAM
Penn Schoen Berland strengthens India presence with 2nd office
MUMBAI: Penn Schoen Berland (PSB), a global research based strategic communications advisory which is a part of Y&R Brands and WPP, launched its second office in India at Mumbai.
The agency started its South Asia operations in April 2011 with the launch of its Gurgaon office.
Along with the launch of Mumbai office, PSB also announced the introduction of Capital Market Communications (CMC) to its bouquet of services. PSB will help create business and financial communication roadmaps that will guide CEOs and CFOs of publicly traded companies to maximise returns to their shareholders.
Chartered accountant and an investor relations expert Mehul Mehta with close to 15 years of experience has joined PSB Mumbai as a director and will lead the CMC team.
PSB South Asia MD and CEO Ashwani Singla said, “As the Indian economy tries to regain its strength; companies have their own challenges as they struggle to sustain investor’s interest in them. Combining our research and capital market communications capabilities will provide clients with deep insights and an actionable programme to protect and enhance shareholder value.” He further added, “Mumbai being the financial capital of the country, it was only appropriate that we take this opportunity to expand our presence.”
PSB brings the lessons learnt from its campaign trails into the board room to help companies negotiate their corporate image and corporate affairs challenges. Almost 30 years old now, PSB serves Fortune 100 Corporations, Hollywood Studios and has worked with nearly 30 presidents and prime ministers around the world.
PSB South Asia serves clients comprising Indian transnationals and multinational corporations operating in the Indian Sub-continent, South East Asia and The Middle East.
MAM
Beacon Group appoints Dr Rajesh Patel as Group CEO
36-year healthcare veteran to lead Beacon Diagnostics, Vector Biotek, Biogeny.
MUMBAI: A new chief, a fresh diagnosis and a sharper prescription for growth. Beacon Group has appointed Dr Rajesh Patel as its Group Chief Executive Officer, effective April 1, 2026, signalling a decisive push to scale its presence in the diagnostics and IVD space. Patel steps into the role with 36 years of experience across the healthcare and diagnostics industry, bringing a career shaped by leadership roles spanning sales, marketing, business development and operational strategy. His mandate is both expansive and precise: to steer the group’s overall strategic direction while tightening coordination across its three core entities Beacon Diagnostics, Vector Biotek and Biogeny Diagnostics.
In practical terms, that means driving cross-company synergies, accelerating market expansion and strengthening organisational capability areas increasingly critical as diagnostic players compete for scale in a fragmented yet rapidly evolving healthcare ecosystem. The group is positioning itself to capture unmet demand across chain laboratories, key accounts and standalone labs, segments that remain underserved despite growing diagnostic needs.
The appointment comes at a time when the In Vitro Diagnostics (IVD) sector in India is entering a more competitive and innovation-led phase, with companies focusing not just on product pipelines but also on service delivery, integration and customer-centric models. Beacon’s leadership appears to be betting that Patel’s execution-focused approach can help translate ambition into operational momentum.
Welcoming the appointment, Chairman Dr D K Joshi described Patel’s induction as a strategic move aligned with the group’s long-term vision, emphasising the role of leadership depth in navigating the next phase of growth.
For Beacon Group, the message is clear, in a sector where precision matters, leadership is the new differentiator—and this appointment is intended to set the tone for what comes next.
